Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY) is a healthcare company (biotechnology) based in the United States. The share price is $16.93, down 2.00% on the day, which values the company at $3.74B. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.
Key facts
- Share price
- $16.93−2.00% today
- Market value
- $3.74B
- Funk Score
- 38/100
- Against its own history
- Well above its usual priceusual price $5.90
- 200-week average
- $9.4879% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Relay Therapeutics, Inc. in more detail
RLAY trades at -10.8× next year's expected earnings, 361.3× sales. Measured against its own history, the price is 187% above what its usual multiples would imply ($5.90) — well above its usual price. It sits 79% above its 200-week average of $9.48.
Over the last five fiscal years Relay Therapeutics, Inc. has compounded revenue -28.6% a year. Its Funk Score is 38 out of 100 (financial strength 8.3, profitability 2.0, growth 4.7, value 0.0, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Heavy stock-based pay.
3 of the superinvestors tracked here hold RLAY, including Julian and Felix Baker (0.3% of the portfolio), Louis Bacon (0.2% of the portfolio), Stanley Druckenmiller (0.1% of the portfolio).
Superinvestors holding RLAY
3 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors0.27% of portfolio · $52.9M · added · Q2 2026
- Louis Bacon Moore Capital Management0.15% of portfolio · $5.5M · trimmed · Q3 2026
- Stanley Druckenmiller Duquesne Family Office0.15% of portfolio · $6.5M · new · Q2 2026
Relay Therapeutics, Inc. (RLAY): questions and answers
What is Relay Therapeutics, Inc.'s market cap?
Relay Therapeutics, Inc. is valued at $3.74B at a share price of $16.93.
Is RLAY overvalued or undervalued?
Against its own history, RLAY is well above its usual price: the price is 187% above the $5.90 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is RLAY above its 200-week moving average?
Yes. RLAY is 78.6% above its 200-week average of $9.48. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Relay Therapeutics, Inc. growing?
Over the last five fiscal years Relay Therapeutics, Inc.'s revenue grew -28.6% a year.
Does RLAY pay a dividend?
Relay Therapeutics, Inc. does not currently pay a regular dividend.
Which famous investors own RLAY?
In their latest quarterly filings, Julian and Felix Baker (0.3% of the portfolio), Louis Bacon (0.2% of the portfolio), Stanley Druckenmiller (0.1% of the portfolio) hold RLAY. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Relay Therapeutics, Inc. (RLAY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RLAY
Underlying data: Yahoo Finance; company filings with the SEC.